Tetra Bio-Pharma Inc.
TBPMF · OTC
11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | -0.08 | -0.08 | 2.00 |
| FCF Yield | -26.82% | -44.34% | -24.83% | -6.26% |
| EV / EBITDA | -1.98 | -2.44 | -5.15 | -9.10 |
| Quality | ||||
| ROIC | -739.13% | -103.13% | -59.72% | -36.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 39.82% |
| Cash Conversion Ratio | 0.48 | 0.93 | 1.22 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | – |
| Free Cash Flow Growth | -21.29% | -23.83% | -85.14% | -104.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.03 | 0.15 | 0.89 |
| Interest Coverage | -13.11 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 2,467.74 |